Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modern Chinese Medicine Group Co's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was HK$-0.03.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.02.
During the past 12 months, Modern Chinese Medicine Group Co's average earnings per share (NRI) Growth Rate was -181.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Modern Chinese Medicine Group Co's EPS without NRI or its related term are showing as below:
During the past 9 years, Modern Chinese Medicine Group Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 35.20% per year. The lowest was -45.70% per year. And the median was 22.90% per year.
HKSE:01643's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.7 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Modern Chinese Medicine Group Co (HKSE:01643) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Modern Chinese Medicine Group Co EPS without NRI Related Terms
Modern Chinese Medicine Group Co EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Chinese Medicine Group Co EPS without NRI Chart
HKSE:01643 vs LLY, JNJ, ABBV: EPS without NRI Comparison
For the Drug Manufacturers - General subindustry, Modern Chinese Medicine Group Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modern Chinese Medicine Group Co PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Modern Chinese Medicine Group Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Modern Chinese Medicine Group Co's PE Ratio without NRI falls into.
Modern Chinese Medicine Group Co EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Chinese Medicine Group Co (HKSE:01643) has a EPS without NRI of HK$-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Modern Chinese Medicine Group Co and its competitors. According to the industry distribution chart, Modern Chinese Medicine Group Co ranks #999999 out of 787 companies in the Drug Manufacturers industry.
Is Modern Chinese Medicine Group Co's EPS without NRI too high?
Modern Chinese Medicine Group Co's current EPS without NRI is HK$-0.02. Based on the distribution chart, Modern Chinese Medicine Group Co ranks #999999 out of 787 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Modern Chinese Medicine Group Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Modern Chinese Medicine Group Co's EPS without NRI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Modern Chinese Medicine Group Co ranks #999999 out of 787 companies for EPS without NRI. This places Modern Chinese Medicine Group Co in the lower half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Modern Chinese Medicine Group Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modern Chinese Medicine Group Co's current EPS without NRI is HK$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Chinese Medicine Group Co stock overvalued right now?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co (HKSE:01643) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.84 — trading 460% above its estimated fair value. The current EPS without NRI is HK$-0.02. Modern Chinese Medicine Group Co's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Modern Chinese Medicine Group Co (HKSE:01643), the current EPS without NRI is HK$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Modern Chinese Medicine Group Co (HKSE:01643) Overvalued in 2026?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co stock appears to be overvalued.
The current stock price of HK$0.84 is trading 460% above its estimated GF Value™ of HK$0.15.
GuruFocus considers Modern Chinese Medicine Group Co to be Significantly Overvalued.
Key valuation signals for HKSE:01643:
EPS without NRI: HK$-0.02
GF Value™: HK$0.15 vs. price of HK$0.84 (460% above fair value)
No single metric tells the full story. See the HKSE:01643 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Modern Chinese Medicine Group Co Ltd is engaged in the production of Proprietary Chinese Medicines. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include liver protection tablets, Shanmei capsules, Qi and blood supplement pills, and Xiaohuoluo pills, among others. Geographically, the company derives its key revenue from the People's Republic of China.
59GF Score
Get the complete analysis for HKSE:01643
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01643 has been successfully added to your 
